This site contains promotional information intended only for healthcare professionals resident in the United Kingdom

Visit Pfizer Medical site

Menu

Close

Sign InLog Out
  • EN
Single LinkDropdownLabelLinkLinkLinkLinkLinked DropdownLabelLinkLinkLinkLinkMega MenuHeading

Example of description text sitting alongside header

LabelLinkLinkLinkLinkLabelLinkLinkLinkLinkLabelLinkLinkLinkLink
Linked Mega MenuHeading

Example of description text sitting alongside header

LabelLinkLinkLinkLinkLabelLinkLinkLinkLinkLabelLinkLinkLinkLink
EN - EnglishSelect a languageLanguagesEN - EnglishFR - Françias

Menu

Close

Sign InLog Out
  • EN
Single LinkDropdownLabelLinkLinkLinkLinkLinked DropdownLabelLinkLinkLinkLinkMega MenuHeading

Example of description text sitting alongside header

LabelLinkLinkLinkLinkLabelLinkLinkLinkLinkLabelLinkLinkLinkLink
Linked Mega MenuHeading

Example of description text sitting alongside header

LabelLinkLinkLinkLinkLabelLinkLinkLinkLinkLabelLinkLinkLinkLink
EN - EnglishSelect a languageLanguagesEN - EnglishFR - Françias
Search

Menu

Close

Sign In or RegisterLog Out
Pfizer MedicinesTherapy AreasExplore ContentEventsVideosMaterialsFeatured ArticlesLet’s ConnectSupplyAlliance HealthcareOff-contract claims

Adverse event reporting can be found at the bottom of the page

Menu

Close

OverviewDosingTolerability ProfileSupport and ResourcesFluoropyrimidine intoleranceUse in patients with fluoropyrimidine intolerancePatient profiles
Explore more
MaterialsVideosEvents

Prescribing Information for TOMUDEX® (raltitrexed) and adverse event reporting information can be found at the bottom of the page.
 

Tolerability ProfileUndesirable effects1

As with other cytotoxic drugs, raltitrexed may be associated with certain adverse drug reactions. These mainly include reversible effects on the haematopoietic system, liver enzymes and gastrointestinal tract. The table below presents the possible very common (≥1/10) and common (≥1/100 to <1/10) adverse drug reactions occurring with TOMUDEX treatment. For the full list of adverse events, please refer to the TOMUDEX SPC.

a Leukopenia (neutropenia in particular), anaemia and thrombocytopenia, alone or in combination, are usually mild to moderate and occur in the first or second week after treatment and recover by the third week.

b Severe (WHO grade 3 and 4) leukopenia (neutropenia in particular) and thrombocytopenia of WHO grade 4 can occur and may be life-threatening or fatal especially if associated with signs of gastrointestinal toxicity.

c Nausea and vomiting are usually mild (WHO grade 1 and 2), occur usually in the first week following the administration of Tomudex, and are responsive to antiemetics.

d Diarrhoea is usually mild or moderate (WHO grade 1 and 2) and can occur at any time following the administration of Tomudex. However, severe diarrhoea (WHO grade 3 and 4) can occur, and may be associated with concurrent haematological suppression especially leukopenia (neutropenia in particular). Subsequent treatment may need to be discontinued or dose reduced according to the grade of toxicity.

e Diarrhoea and vomiting may be severe and if untreated may proceed to dehydration, hypovolaemia and renal impairment

Asthenia and fever were usually mild to moderate following the first week of administration of Tomudex and reversible. Severe asthenia can occur and may be associated with malaise and a flu-like syndrome.

g Increases in AST and ALT have usually been asymptomatic and self-limiting when not associated with progression of the underlying malignancy.

Contraindications1

  • Hypersensitivity to the active substance or to any of the excipients.
  • Raltitrexed should not be used in pregnant women, in women who may become pregnant during treatment or women who are breast feeding. Pregnancy should be excluded before treatment with raltitrexed is commenced. 
  • Raltitrexed is contraindicated in patients with severe renal impairment (creatinine clearance < 25ml/min).
  • Administration of leucovorin (folinic acid), folic acid or vitamin preparations containing these agents with raltitrexed is contraindicated.

Special Warnings and Precautions for Use1

  • Raltitrexed must only given by or under the supervision of a physician who is experienced in cancer chemotherapy, and in the management of chemotherapy-related toxicity. Patients undergoing therapy should be subject to appropriate supervision so that signs of possible toxic effects or adverse reactions (particularly diarrhoea) may be detected and treated promptly.
  • In common with other cytotoxic agents of this type, caution is necessary in patients with depressed bone marrow function, poor general condition, or prior radiotherapy.
  • Patients whose disease progressed on previous treatment for advanced disease with 5-fluorouracil based regimens may also be resistant to the effects of raltitrexed.
  • Elderly patients are more vulnerable to the toxic effects of raltitrexed. Since renal function tends to decline with age and the plasma clearance of raltitrexed is reduced with renal function impairment, there is a potential for accumulation of raltitrexed in elderly patients. Extreme care should be taken to ensure adequate monitoring of adverse reactions especially signs of gastrointestinal toxicity (diarrhoea or mucositis) and myelosuppression (neutropenia, thrombocytopenia, infection) and dose should be reduced and /or delayed as appropriate. A proportion of the raltitrexed is excreted via the faecal route, therefore patients with mild to moderate hepatic impairment should be treated with caution.
  • Treatment with raltitrexed in patients with severe hepatic impairment is not recommended.
  • It is recommended that pregnancy should be avoided during treatment and for at least 6 months after cessation of treatment if either partner is receiving raltitrexed.
  • There is no clinical experience with extravasation. However, perivascular tolerance studies in animals did not reveal any significant irritant reaction.
  • Raltitrexed is a cytotoxic agent and should be handled according to normal procedures adopted for such agents.

Drug-Drug Interactions1

  • No specific clinical drug - drug interaction studies have been conducted in man.
  • Leucovorin (folinic acid), folic acid or vitamin preparations containing these agents must not be given immediately prior to or during administration of raltitrexed, since they may interfere with its action.
  • Clinical trials evaluating the use of raltitrexed in combination with other anti-tumour therapies are currently ongoing.
  • Raltitrexed is 93% protein bound and while it has the potential to interact with similarly highly protein bound drugs, no displacement interaction with warfarin has been observed in vitro. Data suggest that active tubular secretion may contribute to the renal excretion of raltitrexed, indicating a potential interaction with other actively secreted drugs such as non-steroidal anti-inflammatory drugs (NSAIDS). However, a review of the clinical trial safety database did not reveal evidence of clinically significant interaction in patients treated with raltitrexed who also received concomitant NSAIDS, warfarin and other commonly prescribed drugs.
Scroll left to view table
Fluoropyrimidine Intolerance

Learn about TOMUDEX use in patients with fluoropyrimidine intolerance

Find out moreLoading
Patient Profiles

Explore more about how TOMUDEX can support your patients 

Explore moreLoading
Dosing

Find out about TOMUDEX treatment and required dosing adjustments 

Learn moreLoading
Medicines

Find out more about other Pfizer products

View MedicinesLoading
Join us!

Sign up or log in now to access further materials and resource

Join NowLoading

References:

  1. TOMUDEX® Summary of Product Characteristics

 


 

Prescribing Information

TOMUDEX:

TOMUDEX® (raltitrexed) 2 mg powder for solution for infusion – Prescribing Information Legal Category: POM. Basic NHS Price: 1 vial £148.75
 

OXALIPLATIN:

Oxaliplatin Vial 50mg/10ml Legal Category: POM. Basic NHS Price: 1 vial £156.75
Oxaliplatin Vial 100mg/20ml Legal Category: POM. Basic NHS Price: 1 vial £313.50
Oxaliplatin Vial 200mg/40ml Legal Category: POM. Basic NHS Price: 1 vial £627.00
Oxaliplatin 5mg/ml Concentrate for Solution for Infusion - Prescribing Information 


FLUOROURACIL:

Fluorouracil Vial 500mg/20ml Legal Category: POM. Basic NHS Price: £64.00
Fluorouracil Vial 25mg/ml Legal Category: POM. Basic NHS Price: £32.00
Fluorouracil 25mg/ml Injection - Prescribing Information

Fluorouracil Vial 50mg/ml Legal Category: POM. Basic NHS Price: £64.00
Fluorouracil Vial 500mg/10ml Legal Category: POM. Basic NHS Price: £32.00
Fluorouracil Vial 2.5g/50ml Legal Category: POM. Basic NHS Price: £32.00
Fluorouracil 50mg/ml Injection - Prescribing Information



 

PP-TOM-GBR-0001. July 2022

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search 

for MHRA Yellow Card in Google Play or Apple App Store

 

Adverse events should also be reported to Pfizer Medical Information on 01304 616161

PfizerPro Account

To access further materials, resources and receive communication about medicines and vaccines promoted by Pfizer.

Sign In or RegisterAccountSign Out

This site is intended only for healthcare professionals resident in the United Kingdom. If you are a member of the public wishing to access information on a specific medicine, please visit www.medicines.org.uk/emc

 

This website is brought to you by Pfizer Limited, a company registered in England 

and Wales under No. 526209 with its registered office at Ramsgate Road, Sandwich, Kent, CT13 9NJ

 

Copyright © 2024 Pfizer Limited. All rights reserved.

 

VAT registration number GB201048427

PP-UNP-GBR-7866. January 2024
You are now leaving PfizerPro​​​​​
​​​​​​​You are now leaving www.pfizerpro.co.uk. Links to external websites are provided as a resource to the viewer. This website is neither owned or controlled by Pfizer Ltd. 
Pfizer accepts no responsibility for the content or services of the linked site.​​​​​​​​​​​​​​

​​​​​​​PP-PFE-GBR-3858. November 2021​​​​​​​
​​​​​​​
You are now leaving PfizerPro ​​​​​​​
​​​​​​​You are now leaving www.pfizerpro.co.uk. Links to external websites are provided as a resource to the viewer. This website is neither owned nor controlled by Pfizer Ltd. 

Pfizer accepts no responsibility for the content or services of the linked site other than the information or other materials relating to ​​​​​Pfizer medicines or 
business which it has provided or reviewed.

PP-PFE-GBR-3859. November 2021
​​​​​​​
For UK Healthcare Professionals*

These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.

I confirm that I am a healthcare professional* resident in the United Kingdom.

If you select 'No', you will be redirected to Pfizer.co.uk where you will be able to access reference information on Pfizer's prescription medicines.

*The ABPI Code definition for healthcare professional is members of the medical, dental, pharmacy and nursing professionals and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.

PP-UNP-GBR-7812. January 2024

YesNo
You are now leaving PfizerPro​​​​​

​​​​​​​You are now leaving www.pfizerpro.co.uk. Links to external websites are provided as a resource to the viewer. This website is neither owned or controlled by Pfizer Ltd. 

Pfizer accepts no responsibility for the content or services of the linked site.​​​​​​​​​​​​​​

​​​​​​​PP-PFE-GBR-3858. November 2021​​​​​​​
​​​​​​​
You are now leaving PfizerPro
​​​​​​​
​​​​​​​You are now leaving www.pfizerpro.co.uk. Links to external websites are provided as a resource to the viewer. This website is neither owned nor controlled by Pfizer Ltd. 

Pfizer accepts no responsibility for the content or services of the linked site other than the information or other materials relating to ​​​​​Pfizer medicines or 
business which it has provided or reviewed.

PP-PFE-GBR-3859. November 2021
​​​​​​​